These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17697259)

  • 1. Valganciclovir versus IV ganciclovir for therapy of cytomegalovirus viremia: has victory been achieved?
    Avery RK
    Am J Transplant; 2007 Sep; 7(9):2062-3. PubMed ID: 17697259
    [No Abstract]   [Full Text] [Related]  

  • 2. Preemptive valganciclovir for cytomegalovirus infection in hematological patients.
    Focosi D; Benedetti E; Maggi F; Papineschi F; Galimberti S; Ceccherini-Nelli L; Petrini M
    Transpl Infect Dis; 2008 Oct; 10(5):375-6. PubMed ID: 18844864
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients.
    Asberg A; Humar A; Jardine AG; Rollag H; Pescovitz MD; Mouas H; Bignamini A; Töz H; Dittmer I; Montejo M; Hartmann A;
    Am J Transplant; 2009 May; 9(5):1205-13. PubMed ID: 19422345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.
    Razonable RR; Paya CV
    Expert Rev Anti Infect Ther; 2004 Feb; 2(1):27-41. PubMed ID: 15482169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
    Wiltshire H; Paya CV; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Zuideveld KP;
    Transplantation; 2005 Jun; 79(11):1477-83. PubMed ID: 15940035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
    Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
    Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus ulcer. Successful treatment with valganciclovir.
    Lambert EM; Strasswimmer J; Lazova R; Antaya RJ
    Arch Dermatol; 2004 Oct; 140(10):1199-201. PubMed ID: 15492181
    [No Abstract]   [Full Text] [Related]  

  • 8. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
    Humar A; Siegal D; Moussa G; Kumar D
    J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Valganciclovir. Oral treatment of Cytomegalovirus infections].
    Kroes AC
    Ned Tijdschr Geneeskd; 2004 Jun; 148(25):1236-8. PubMed ID: 15301386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral valganciclovir treatment for congenital cytomegalovirus infection.
    Imamura T; Suzutani T; Ogawa H; Asano K; Nomoto M; Matsui T; Momoi N; Ikuta K; Inoue N; Hosoya M
    Pediatr Int; 2011 Apr; 53(2):249-52. PubMed ID: 21501311
    [No Abstract]   [Full Text] [Related]  

  • 11. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.
    Humar A; Kumar D; Preiksaitis J; Boivin G; Siegal D; Fenton J; Jackson K; Nia S; Lien D
    Am J Transplant; 2005 Jun; 5(6):1462-8. PubMed ID: 15888055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Valganciclovir for treatment of cytomegalovirus viremia in patients following allogeneic hematopoietic stem cell transplantation].
    Wang Y; Huang XJ; Xu LP; Liu DH; Chen YH; Han W; Wang J; Liu KY
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(46):3265-7. PubMed ID: 19159551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir.
    Amir J; Wolf DG; Levy I
    Eur J Pediatr; 2010 Sep; 169(9):1061-7. PubMed ID: 20232081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir.
    Mattes FM; Hainsworth EG; Hassan-Walker AF; Burroughs AK; Sweny P; Griffiths PD; Emery VC
    J Infect Dis; 2005 Jan; 191(1):89-92. PubMed ID: 15593008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
    Freeman RB
    Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
    Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
    Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.
    Chawla JS; Ghobadi A; Mosley J; Verkruyse L; Trinkaus K; Abboud CN; Cashen AF; Stockerl-Goldstein KE; Uy GL; Westervelt P; DiPersio JF; Vij R
    Transpl Infect Dis; 2012 Jun; 14(3):259-67. PubMed ID: 22093134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl.
    Burri M; Wiltshire H; Kahlert C; Wouters G; Rudin C
    Pediatr Infect Dis J; 2004 Mar; 23(3):263-6. PubMed ID: 15014306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial.
    Åsberg A; Humar A; Rollag H; Jardine AG; Kumar D; Aukrust P; Ueland T; Bignamini AA; Hartmann A
    Clin Infect Dis; 2016 May; 62(9):1154-60. PubMed ID: 26908810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.